| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 524.4 | 142.3 |
| Profit before tax | -97.7 | -368.7 |
| Net income | -100.3 | -370.0 |
| EPS (diluted, $ a share) | $-0.46 | $-1.75 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +268.4% |
|---|---|
| Operating margin | -17.0% |
10-Q filed with the SEC, NASDAQ: INSM. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Insmed Inc: key numbers
- Share price
- $121.86Close, Nov 17
- Market cap
- $26.7B
- Shares outstanding
- 219.38MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Insmed Inc
All →Insmed Financial Results
Insmed reported third-quarter 2026 total revenues of $524.4 million, driven by strong commercial momentum for BRINSUPRI and ARIKAYCE. The company raised its full-year 2026 revenue guidance for both products following the successful launch of BRINSUPRI in Japan and continued growth in the U.S. market.
“The third quarter marked another period of meaningful progress, defined by commercial momentum, regulatory achievements, and advancement across our diversified pipeline. BRINSUPRI’s U.S. launch continues to exceed expectations and ARIKAYCE continues to grow while in its ninth year on the market. This performance supports our decision to raise the low end of our full-year 2026 revenue guidance for both products.”
Will Lewis, Chair and Chief Executive Officer of Insmed
Insmed Leadership Change
Insmed Incorporated appointed Paul Hudson, former CEO of Sanofi and Novartis, and Utpal Koppikar, CFO of Verily Health, to its Board of Directors effective October 19, 2026. Both directors will receive an annual cash retainer of $65,000 plus committee fees and an initial RSU grant valued at approximately $585,000. The appointments add significant global biopharma leadership and financial expertise to the board as the company advances its rare disease pipeline.
Insmed Leadership Change
Sara Bonstein is stepping down as Chief Financial Officer of Insmed, effective October 30, 2026, to pursue a broader leadership role. The company has initiated a search for a successor and reaffirmed its full-year 2026 revenue guidance for BRINSUPRI and ARIKAYCE.
- Earnings call
- Oct 29, 2026, 8:00 AM ET